Ardelyx (ARDX) Common Equity (2013 - 2026)
Ardelyx's (ARDX) quarterly Common Equity came in at $148.6 million in Q1 2026, up 2.02% YoY from $145.7 million in Q1 2025, and down 10.98% on a QoQ basis from $166.9 million in Q4 2025.
Ardelyx (ARDX) Common Equity (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Common Equity data on file, last reported at $148.6 million in Q1 2026.
- Quarterly Common Equity rose 2.02% year-over-year to $148.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.6 million (up 2.02% YoY) and the FY2025 annual result came in at $166.9 million, down 3.66% from the prior year.
- Common Equity eased to $148.6 million in Q1 2026, from $166.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $191.2 million in Q3 2023 to a low of $53.0 million in Q2 2022.
- A 5-year average of $133.7 million and a median of $147.0 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 54.88% — and 2023, when it soared 185.91%.
- Tracing ARDX's Common Equity over 5 years: stood at $98.3 million in 2022, then surged by 69.65% to $166.8 million in 2023, then gained by 3.88% to $173.3 million in 2024, then dropped by 3.66% to $166.9 million in 2025, then slipped by 10.98% to $148.6 million in 2026.
- The last three Common Equity figures came in at $148.6 million (Q1 2026), $166.9 million (Q4 2025), and $154.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 149.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149.01 Mn |
| Mar 31, 2026 | 148.62 Mn |
| Dec 31, 2025 | 166.95 Mn |
| Sep 30, 2025 | 154.28 Mn |
| Jun 30, 2025 | 139.53 Mn |
| Mar 31, 2025 | 145.68 Mn |
| Dec 31, 2024 | 173.29 Mn |
| Sep 30, 2024 | 158.30 Mn |
| Jun 30, 2024 | 146.99 Mn |
| Mar 31, 2024 | 150.89 Mn |
| Dec 31, 2023 | 166.82 Mn |
| Sep 30, 2023 | 191.16 Mn |
| Jun 30, 2023 | 123.16 Mn |
| Mar 31, 2023 | 125.42 Mn |
| Dec 31, 2022 | 98.33 Mn |
| Sep 30, 2022 | 66.86 Mn |
| Jun 30, 2022 | 53.04 Mn |
| Mar 31, 2022 | 64.19 Mn |
| Dec 31, 2021 | 82.62 Mn |
| Sep 30, 2021 | 81.43 Mn |